Andrew Rowland is Professor of Clinical Pharmacology and Precision Medicine Lead at Flinders University. His research focuses on improving the safe, effective and equitable use of cancer medicines by understanding how life stage, disease, environmental factors and individual biology influence treatment exposure and response. A central theme of his work is translating precision medicine discoveries into clinically useful tools that can better predict who will benefit from treatment, who is at risk of harm and how medicines can be optimised for people affected by cancer.

Professor Rowland is internationally recognised for pioneering the use of extracellular vesicles as advanced biomarkers to characterise drug exposure and treatment response, with this work informing early drug development, clinical trial design and cancer treatment guidelines. His research integrates clinical pharmacology, biomarker science, artificial intelligence and stakeholder engagement to address complex challenges in cancer therapy.

He has co-authored more than 160 peer-reviewed publications, attracted more than $11 million in competitive research funding as a lead investigator, and received multiple awards for translational pharmacology and precision medicine. He holds national and international leadership roles across clinical pharmacology and therapeutics, including serving on the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Board of Director and Chairing the International Society for Extracellular Vesicles working group on Clinical Applications of Blood EVs, and is strongly committed to consumer-engaged research and community advocacy.